Trial pre-screening

--- MRN-100291 ---
Most recent Hemoglobin A1c on file is 7.51% dated 2022-10-07, which is outside the 12-month window relative to recent encounters through 2025-10-31; the SQL pull may be using an older/mislabeled result. Patient also carries active anemia and is on ferrous sulfate, which can affect A1c reliability, and is on chronic NSAIDs (ibuprofen, naproxen) with no recent renal labs shown. PROCEED TO COORDINATOR / CHECK FIRST: confirm a valid A1c within the last 12 months and check renal function given chronic NSAID use.

--- MRN-100459 ---
Active problem list includes Diabetes mellitus type 2 (onset 2024-04-06) with A1c well-controlled at 6.92% (most recent 2026-04-18), but no oral antidiabetic medication appears anywhere in the active medication list — raising the question of whether he is actually on oral therapy or diet-controlled/untreated, which affects eligibility for an "oral-therapy" protocol. He also has significant cardiac history (CABG, ischemic heart disease) and a notably elevated creatinine (2.873 mg/dL, 2018), relevant to drug safety/dosing. PROCEED TO COORDINATOR / CHECK FIRST: verify current diabetes medication regimen (oral agent present or absent) and confirm current renal function.

--- MRN-100998 ---
No Hemoglobin A1c value appears in the recent abnormal results (only BMI and creatinine trends are shown), so the required "A1c in last 12 months" criterion needs source verification. Patient is on metformin despite a markedly elevated creatinine (2.978 mg/dL, most recent 2017), a classic contraindication/dose-limiting factor for metformin, and is also on multiple opioids (fentanyl, oxycodone, hydrocodone/acetaminophen) for chronic pain, which may affect informed consent/participation. PROCEED TO COORDINATOR / CHECK FIRST: confirm a qualifying recent A1c and reassess current renal function relative to metformin use.